Robert Orenstein, DO, Mayo Clinic, Phoenix, AZ; Erik R Dubberke, MD, MSPH, Washington University School of Medicine, St. Louis, MO; Cheryl L Griesbach, RN, Mayo Clinic, Phoenix, AZ; Mary Kay Sobcinski, RN, MHA, Rebiotix Inc, Roseville, MN
Managing recurrent C. difficile infection is challenging due to the limited effectiveness of current treatment options. Fecal transplant appears to be an effective mechanism for managing multiply recurrent C. difficile infection. Studies have looked at the acceptability of fecal transplant. However, little is known about the patients who seek fecal transplant for recurrent C. difficile infection. We report the demographics of subjects enrolled in an ongoing Phase 2 study (PUNCH CD) of RBX2660 (microbiota suspension), a next generation standardized and commercially prepared version of fecal transplant for the treatment of recurrent C. difficile infection.